COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
July 28, 2022 04:00 ET | COMPASS Pathways
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological...
compass_positive_tagline-01.png
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
May 03, 2022 07:00 ET | COMPASS Pathways
Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022        COMPASS...
MN-Chicago_Pic1
Monte Nido & Affiliates Brings Two Residential Eating Disorder Programs to Chicagoland
February 20, 2020 15:50 ET | Monte Nido & Affiliates
CHICAGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Monte Nido & Affiliates, the nation’s leading provider of eating disorder treatment for over 24 years, announces the opening of two residential eating...
Changing the Way the World Thinks About Eating Disorders - A Free Webinar from the Brain & Behavior Research Foundation
November 21, 2019 09:00 ET | Brain & Behavior Research Foundation
New York, Nov. 21, 2019 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation is hosting a free webinar “Changing the Way the World Thinks About Eating Disorders” on Tuesday, December 10,...